Telmisartan improves the metabolic, hematological and inflammasome indices in non-alcoholic fatty liver infiltration: A pilot open-label placebo-controlled study

Al-Nimer, Marwan S.M.; Esmail, Vian Ahmed Wasta; Mohammad, O N

doi:10.29333/ejgm/104568

Search citation statements

Order By: Relevance

Paper Sections

Select...

Treatment Options For Different Pathophysiological Mechanism1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neither telmisartan not placebo improved histopathology findings in MAFLD. 76 Telmisartan side effects included sinus pain and congestion, back pain, diarrhea, sore throat, flu-like symptoms, upset stomach, muscle pain, headache, dizziness, fatigue, and nausea. 77 Despite their potential benefit, ARBs are not used for non-cardiovascular indications because of dose-limiting hypotension.…”

Section: Treatment Options For Different Pathophysiological Mechanismmentioning

confidence: 99%

An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents

Rubin¹,

Bojanić²,

Smolić³

et al. 2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

Liver fibrosis represents a response to chronic liver injury. Metabolic dysfunction-associated fatty liver disease and metabolic dysfunction-associated steatohepatitis are the most common chronic liver diseases, both with increasing incidence. Therefore, there is a great impetus for development of agents targeting these conditions. Accumulating data on possible treatment options for liver fibrosis are emerging in the literature. However, despite extensive research and much effort in the field, approved agents for liver fibrosis are still lacking. In this critical review, we have summarized the main data about specific treatment options for liver fibrosis gained from ongoing clinical trials, with an emphasis on efficacy and safety of these agents.

show abstract

Section: Treatment Options For Different Pathophysiological Mechanismmentioning

confidence: 99%